Cullinan Oncology Inc (CGEM)
11.43
-0.34 (-2.89%)
USD |
NASDAQ |
Feb 06, 14:51
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 449.48M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -8.05% |
Valuation | |
PE Ratio | 5.149 |
PE Ratio (Forward) | Upgrade |
PS Ratio | -- |
Price to Book Value | 0.7669 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -- |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | -- |
News
Headline
Wire
Time (ET)
MT Newswires
02/03 09:37
Yahoo
02/02 16:01
Yahoo
11/14 07:00
Yahoo
11/02 08:00
Events
DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
03/17/2023* | -- | Results | Q4 2022 | -- | -0.71 | -- | |
11/14/2022 | -- | Results | Q3 2022 | -- | -0.45 | -- | |
08/10/2022 | -- | Results | Q2 2022 | -- | -0.50 | -- | |
05/16/2022 | -- | Results | Q1 2022 | -- | -0.47 | -- | |
03/17/2022 | -- | Results | Q4 2021 | -0.53 | -0.47 | -10.92% | |
11/09/2021 | -- | Results | Q3 2021 | -0.50 | -0.44 | -14.94% | |
08/10/2021 | -- | Results | Q2 2021 | -0.36 | -0.42 | 14.29% | |
05/14/2021 | -- | Results | Q1 2021 | 0.00 | 0.03 | -- |
*Estimated Date/Time
Earnings
Profile
Edit
Cullinan Oncology Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. |
URL | https://www.cullinanoncology.com |
Investor Relations URL | N/A |
HQ State/Province | Massachusetts |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | N/A |
Next Earnings Release | Mar. 17, 2023 (est.) |
Last Earnings Release | Nov. 14, 2022 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Analyst Coverage
Consensus Rating
|
|
Analyst Recommendation
|
Source: S&P Global
Dividends
Dividend Per Share (TTM) | -- |
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
Yield to Market | 0.00 |
Yield to Sector | 0.00 |
Yield to Industry | 0.00 |
Last Dividend Amt. | -- |
Dividend Frequency | -- |
Last Ex-Dividend Date | -- |
Yield (TTM) | 0% |
Forward Yield | -- |
Payout Ratio | -- |
Cash Payout Ratio | -- |
Consistent Payer (5Y) | No |
Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of February 03, 2023.
Fundamentals
2017
2018
2019
2020
2021
4.00
2.00
1.00
Revenue (TTM) | -- |
Total Expenses (TTM) | 133.88M |
Net Income (TTM) | 105.48M |
Total Assets (Quarterly) | 617.24M |
Total Liabilities (Quarterly) | 31.11M |
Shareholders Equity (Quarterly) | 586.13M |
Cash from Operations (TTM) | -116.85M |
Cash from Investing (TTM) | 261.72M |
Cash from Financing (TTM) | 9.681M |
Ratings
Profile
Edit
Cullinan Oncology Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. |
URL | https://www.cullinanoncology.com |
Investor Relations URL | N/A |
HQ State/Province | Massachusetts |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | N/A |
Next Earnings Release | Mar. 17, 2023 (est.) |
Last Earnings Release | Nov. 14, 2022 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Risk Info
Ownership
Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
Consensus Rating
|
|
Analyst Recommendation
|
Source: S&P Global
Other Resources
Whale Wisdom | 13F Filings |
Seeking Alpha | Call Transcripts |
Nasdaq | Insider Trading |
Nasdaq | Institutional Ownership |
Nasdaq | Option Chain |
SEC | SEC Filings |
CGEM Tweets |